Multivariate analysis of clinical characteristics affecting OS and EFS
| Variable . | n/N (%) . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P† . | HR (95% CI) . | P† . | ||
| TT2 | |||||
| Creatinine ≥ 2.0 mg/dL | 37/334 (11) | 1.75 (1.07, 2.84) | .024 | 1.70 (1.19, 2.43) | .004 |
| LDH ≥ 190 U/L | 114/334 (34) | 1.81 (1.24, 2.66) | .002 | 1.44 (1.13, 1.82) | .003 |
| Cytogenetic abnormalities | 108/334 (32) | 1.77 (1.20, 2.62) | .004 | NS | NS |
| Randomization to thalidomide | 166/334 (50) | NS | NS | 0.75 (0.60, 0.93) | .009 |
| t(4;14) | 47/334 (14) | 1.81 (1.15, 2.85) | .010 | 1.87 (1.35, 2.57) | < .001 |
| 17 gene-defined GEP high-risk* | 50/334 (15) | 2.47 (1.58, 3.85) | < .001 | 2.15 (1.56, 2.96) | < .001 |
| TP53 high-risk | 35/334 (10) | 2.01 (1.22, 3.30) | .006 | 1.44 (1.00, 2.07) | .049 |
| TT3 | |||||
| Age 65 y or older | 50/176 (28) | 2.32 (1.04, 5.22) | .041 | NS | NS |
| β2-microglobulin > 5.5 mg/L | 38/176 (22) | NS | NS | 3.33 (1.68, 6.62) | < .001 |
| Creatinine ≥ 2.0 mg/dL | 58/176 (33) | 3.54 (1.54, 8.16) | .003 | NS | NS |
| Cytogenetic abnormalities | 30/176 (17) | 2.42 (1.08, 5.39) | .031 | NS | NS |
| 17-gene high-risk | 20/176 (11) | 3.19 (1.32, 7.68) | .010 | 3.97 (1.98, 7.97) | < .001 |
| TP53 high-risk | 50/176 (28) | 2.32 (1.04, 5.22) | .041 | 2.51 (1.13, 5.57) | .024 |
| Variable . | n/N (%) . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P† . | HR (95% CI) . | P† . | ||
| TT2 | |||||
| Creatinine ≥ 2.0 mg/dL | 37/334 (11) | 1.75 (1.07, 2.84) | .024 | 1.70 (1.19, 2.43) | .004 |
| LDH ≥ 190 U/L | 114/334 (34) | 1.81 (1.24, 2.66) | .002 | 1.44 (1.13, 1.82) | .003 |
| Cytogenetic abnormalities | 108/334 (32) | 1.77 (1.20, 2.62) | .004 | NS | NS |
| Randomization to thalidomide | 166/334 (50) | NS | NS | 0.75 (0.60, 0.93) | .009 |
| t(4;14) | 47/334 (14) | 1.81 (1.15, 2.85) | .010 | 1.87 (1.35, 2.57) | < .001 |
| 17 gene-defined GEP high-risk* | 50/334 (15) | 2.47 (1.58, 3.85) | < .001 | 2.15 (1.56, 2.96) | < .001 |
| TP53 high-risk | 35/334 (10) | 2.01 (1.22, 3.30) | .006 | 1.44 (1.00, 2.07) | .049 |
| TT3 | |||||
| Age 65 y or older | 50/176 (28) | 2.32 (1.04, 5.22) | .041 | NS | NS |
| β2-microglobulin > 5.5 mg/L | 38/176 (22) | NS | NS | 3.33 (1.68, 6.62) | < .001 |
| Creatinine ≥ 2.0 mg/dL | 58/176 (33) | 3.54 (1.54, 8.16) | .003 | NS | NS |
| Cytogenetic abnormalities | 30/176 (17) | 2.42 (1.08, 5.39) | .031 | NS | NS |
| 17-gene high-risk | 20/176 (11) | 3.19 (1.32, 7.68) | .010 | 3.97 (1.98, 7.97) | < .001 |
| TP53 high-risk | 50/176 (28) | 2.32 (1.04, 5.22) | .041 | 2.51 (1.13, 5.57) | .024 |
The multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level. A multivariate P > .05 indicates a variable forced into the model, with significant variables chosen by stepwise selection.
HR indicates hazard ratio; CI, 95% confidence interval; P, probability value from Wald χ2 test in Cox regression; NS, not statistically significant at the .05 level on multivariate analysis; LDH, lactate dehydrogenase; GEP, gene expression profile; and PI, proliferation index.25
17 gene-defined GEP high-risk has been described elsewhere.1
Variables for which P > .05: age, race, sex, isotype, hemoglobin, C-reactive protein, MRI lesions, and albumin.